A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC

NCT ID: NCT05545852

Last Updated: 2023-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the feasibility and safety of gasless transaxillary posterior endoscopic thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) and open radical thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) as the current standard surgical treatment mode in terms of feasibility and safety of radical thyroidectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects that suffering from papillary thyroid carcinoma will be randomized into Study Group (gasless transaxillary posterior endoscopic thyroidectomy ) or Control Group (conventional open thyroidectomy). Measure the outcomes as following, early complication rate, life quality score, the number of dissected lymph nodes, the volume of residual gland, 3-year recurrence rate, operation duration, hospital stays, hospitalization expense, and inflammatory and immune response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Papillary Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Group Type EXPERIMENTAL

GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)

Intervention Type PROCEDURE

Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Control Group

Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Group Type ACTIVE_COMPARATOR

COT(Conventional Open Thyroidectomy)

Intervention Type PROCEDURE

Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)

Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Intervention Type PROCEDURE

COT(Conventional Open Thyroidectomy)

Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient's informed consent;
* 18 years old \< age \< 70 years old;
* Papillary thyroid carcinoma (Bethesda grade V-VI) was pathologically diagnosed by fine needle aspiration biopsy of the primary thyroid tumor before surgery;
* Color Doppler TI-RADS 4c-5 of primary thyroid tumor;
* The preoperative clinical staging is T1, N0-1a, M0 (see diagnostic criteria for details; according to AJCC-8th TNM tumor staging);
* It is expected that R0 surgical results can be obtained by performing single thyroid lobectomy and isthmus resection + ipsilateral central lymph node dissection;
* Preoperative ASA score I-III.

Exclusion Criteria

* Pregnant or lactating patients;
* Suffering from serious mental illness;
* Preoperative imaging examinations suggest that the tumor is located in the thyroid isthmus or involves bilateral lobes;
* Preoperative imaging examinations suggest the possibility of cervical lateral lymph node or distant metastasis;
* Hashimoto's thyroiditis combined with hyperthyroidism or abnormal thyroid function;
* History of neck surgery;
* History of thyroid surgery (including ablation therapy for thyroid nodules);
* Family history of thyroid cancer;
* History of childhood ionizing radiation exposure;
* History of other malignant diseases within 5 years;
* A history of unstable angina or myocardial infarction within 6 months;
* History of cerebral infarction or cerebral hemorrhage within 6 months;
* History of continuous systemic corticosteroid therapy within 1 month;
* Concurrent surgical treatment of other diseases is required;
* Patients who are judged by the investigator to be unsuitable to participate in this trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nanfang Hospital, Southern Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shangtong Lei, Dr.

Role: PRINCIPAL_INVESTIGATOR

Nanfang Hospital, Southern Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Baihui Sun, Dr.

Role: CONTACT

+8602062787170

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Baihui Sun, Dr.

Role: primary

+8602062787170

Related Links

Access external resources that provide additional context or updates about the study.

http://www.chictr.org.cn/showproj.aspx?proj=51290

Registration on Chinese Clinical Trial Registry

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NFEC-2021-324

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.